AS1411-conjugated gold nanospheres and their potential for breast cancer therapy
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
// Mohammad T. Malik 1, 5 , Martin G. O’Toole 2 , Lavona K. Casson 1, 5 , Shelia D. Thomas 1, 5 , Gina T. Bardi 1, 5 , Elsa Merit Reyes-Reyes 1, 5 , Chin K. Ng 3 , Kyung A. Kang 4 , Paula J. Bates 1, 5 1 Departments of Medicine, University of Louisville, Louisville, Kentucky, USA 2 Departments of Bioengineering, University of Louisville, Louisville, Kentucky, USA 3 Departments of Radiology, University of Louisville, Louisville, Kentucky, USA 4 Departments of Chemical Engineering, University of Louisville, Louisville, Kentucky, USA 5 Departments of the Molecular Targets Group of the James Graham Brown Cancer Center, University of Louisville, Louisville, Kentucky, USA Correspondence to: Mohammad T. Malik, e-mail: tariq.malik@louisville.edu Paula J. Bates, e-mail: paula.bates@louisville.edu Keywords: targeted therapy, nanomedicine, triple negative breast cancer, G-quadruplex, nanoparticles Received: May 11, 2015 Accepted: May 22, 2015 Published: June 03, 2015 ABSTRACT AS1411 is a quadruplex-forming DNA oligonucleotide that functions as an aptamer to target nucleolin, a protein present on the surface of cancer cells. Clinical trials of AS1411 have indicated it is well tolerated with evidence of therapeutic activity, but improved pharmacology and potency may be required for optimal efficacy. In this report, we describe how conjugating AS1411 to 5 nm gold nanospheres influences its activities in vitro and in vivo . We find that the AS1411-linked gold nanospheres (AS1411-GNS) are stable in aqueous and serum-containing solutions. Compared to unconjugated AS1411 or GNS linked to control oligonucleotides, AS1411-GNS have superior cellular uptake and markedly increased antiproliferative/cytotoxic effects. Similar to AS1411, AS1411-GNS show selectivity for cancer cells compared to non-malignant cells. In a mouse model of breast cancer, systemic administration of AS1411-GNS could completely inhibit tumor growth with no signs of toxicity. These results suggest AS1411-GNS are promising candidates for clinical translation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nucleolin Targeting AS1411 Modified Protein Nanoparticle for Antitumor Drugs Delivery
Wu, J., Song, C., Jiang, C., Shen, X., Qiao, Q., & Hu, Y. (2013) · Molecular Pharmaceutics · doi:10.1021/mp300686g · Cited by 125
Cited by
DNA Quadruple Helices in Nanotechnology
Mergny, J.-L., & Sen, D. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00629 · Cited by 346
G-quadruplex oligonucleotide AS1411 as a cancer-targeting agent: Uses and mechanisms
Bates, P. J., Reyes-Reyes, E. M., Malik, M. T., Murphy, E. M., O'Toole, M. G., & Trent, J. O. (2017) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2016.12.015 · Cited by 345
Self-citationTherapeutic applications of AS1411 aptamer, an update review
Yazdian-Robati, R., Bayat, P., Oroojalian, F., Zargari, M., Ramezani, M., Taghdisi, S. M., & Abnous, K. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2019.11.118 · Cited by 288
Ghahremani, F., Kefayat, A., Shahbazi-Gahrouei, D., Motaghi, H., Mehrgardi, M. A., & Haghjooy-Javanmard, S. (2018) · Nanomedicine · doi:10.2217/nnm-2018-0180 · Cited by 70
Wang, C., Liu, B., Xu, X., Zhuang, B., Li, H., Yin, J., Cong, M., Xu, W., & Lu, A. (2016) · Oncotarget · doi:10.18632/oncotarget.7073 · Cited by 67
Metadata
- Authors
- Malik, M. T., O’Toole, M. G., Casson, L. K., Thomas, S. D., Bardi, G. T., Reyes-Reyes, E. M., Ng, C. K., Kang, K. A., & Bates, P. J.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2015-06-03
- Volume
- 6
- Issue
- 26
- Pages
- 22270-22281
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W1892505945
- Cited by
- 116
- References
- 1
- FWCI
- 4.84
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.